Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Group A and C Meningococcal Polysaccharide Conjugate Vaccine
- Development stage
- Approved
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Group A and C Meningococcal Polysaccharide Conjugate Vaccine is an active immunizing agent designed to prevent infection by *Neisseria meningitidis* serogroups A and C. The vaccine consists of purified capsular polysaccharides from groups A and C, each covalently linked (conjugated) to a carrier protein such as CRM197 or diphtheria toxoid. This conjugation enhances the immune response by inducing T-cell dependent immunity, resulting in higher antibody titers, immune memory, and improved protection compared to plain polysaccharide vaccines[5][8]. The primary indication is the prevention of invasive diseases caused by *Neisseria meningitidis* serogroups A and C, including meningitis and septicemia. It is recommended for individuals at increased risk due to age (infants, children, adolescents), underlying health conditions, or exposure in endemic areas[2][5]. Menactra (Sanofi) uses diphtheria toxoid as the carrier protein; Menveo (GSK) uses CRM197[1][2].
- Brand names
- MenactraMenveo
- Other names
- meningococcal ac conjugate vaccinemeningococcal group a and c conjugate vaccinemeningococcal polysaccharide diphtheria conjugate vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharide
Beyond the preview
Go deeper on Group A and C Meningococcal Polysaccharide Conjugate Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Group A and C Meningococcal Polysaccharide Conjugate Vaccine.